Aeovian Pharmaceuticals, Inc. announced that it has raised $50 million in a round of funding led by new investor, Hevolution Foundation on March 28, 2024. The transaction included participation from returning investors, Apollo Health Ventures, Sofinnova Investment, Inc., venBio LLC, Evotec SE, b2venture AG.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
10.48 EUR | +2.04% | +8.88% | -50.75% |
14/05 | Centogene, Evotec Discover New Molecule for Potential Gaucher Disease Treatment | MT |
14/05 | Centogene N.V and Evotec SE Discovers Promising New Molecule to Treat Gaucher Disease | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-50.75% | 1.97B | |
+29.77% | 49.18B | |
+1.00% | 42.11B | |
+50.47% | 40.37B | |
-5.26% | 28.85B | |
+13.68% | 26.09B | |
-22.99% | 18.71B | |
+8.22% | 13.26B | |
+32.41% | 12.32B | |
-1.62% | 11.99B |
- Stock Market
- Equities
- EVT Stock
- News Evotec SE
- Aeovian Pharmaceuticals, Inc. announced that it has received $50 million in funding from Hevolution Foundation, Apollo Health Ventures, Sofinnova Investment, Inc., venBio LLC, Evotec SE, b2venture AG